Novakand Pharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 26, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	5	19	133	370	169	344
Market Cap Growth	-96.58%	-85.70%	-64.21%	119.29%	-50.92%	-51.68%
Enterprise Value	-11	-3	75	312	101	226
Last Close Price	0.04	0.16	1.09	4.44	2.08	5.99
PB Ratio	0.32	1.26	2.13	7.77	1.58	2.81
P/TBV Ratio	0.32	1.26	2.99	12.49	1.97	3.39
Debt / Equity Ratio	-	-	-	-	-	0.01
Net Debt / Equity Ratio	-1.07	-1.07	-0.74	-0.96	-0.89	-0.86
Net Debt / EBITDA Ratio	-	-	1.07	0.72	1.82	2.27
Net Debt / FCF Ratio	0.53	0.53	0.79	0.82	2.00	2.40
Quick Ratio	9.89	9.89	10.39	2.61	6.94	10.72
Current Ratio	10.03	10.03	10.61	2.65	7.20	10.72
Return on Equity (ROE)	-122.09%	-122.09%	-81.05%	-83.96%	-45.75%	-46.90%
Return on Assets (ROA)	-44.23%	-44.23%	-43.53%	-44.32%	-25.91%	-27.11%
Return on Capital Employed (ROCE)	-196.50%	-196.50%	-74.10%	-138.60%	-49.30%	-38.20%
Earnings Yield	-971.88%	-249.18%	-33.62%	-17.52%	-31.07%	-13.28%
FCF Yield	-	-159.81%	-44.15%	-15.03%	-28.16%	-12.82%
Buyback Yield / Dilution	-5.08%	-5.08%	-44.85%	-36.90%	-3.91%	-54.18%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.